| Name | Title | Contact Details |
|---|---|---|
Tom Kochy |
SVP, Head of Global Product Strategy and Commercial | Profile |
Rupert D`Souza |
Chief Financial Officer | Profile |
Christopher DeRespino |
Acting Chief Financial Officer and Chief Business Officer | Profile |
Leone Patterson |
President and Chief Financial Officer | Profile |
Jennifer DeBerardinis |
Vice President Procurement | Profile |
With Vytelle, cattle producers increase accuracy of feed intake and bodyweight measurement, improve certainty of genetic selection and accelerate progress.
CepTor Corporation is a Cockeysville, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
Access Bio Inc is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advanced Enzyme Technologies Limited is engaged in business of manufacturing and sale of enzymes. The Companys geographical segments include Within India and Outside India. It provides solutions to industries, such as human healthcare and nutrition, a...